CanSinoBIO Reports Positive Primary Immunization Data From Phase II Polio Vaccine Trial

By Public Technologies
  • CanSinoBIO reported positive primary immunization data from key groups in its Phase II VLP-Polio vaccine trial in Indonesia, supporting further development.
  • Main on-site trial activities are complete. Development progress was presented at the 2026 WHO Global Polio Vaccine Consultation in Geneva.
  • China's National Medical Products Administration granted clinical trial approval in July 2025. The Gates Foundation funds clinical research, manufacturing scale-up and combination-vaccine development.
  • The vaccine does not require infectious live poliovirus in production, reducing the risk of viral release during manufacturing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cansino Biologics Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.